Daiichi Sankyo takes another big whack at U.S. sales operations, cutting 280 jobs
admin 6th March 2018 Uncategorised 0Daiichi Sankyo, which has struggled financially since losing exclusivity for its blood pressure drug Benicar, is again swinging the job-cutting ax in the U.S., eliminating 280 jobs from its commercial operations.
More: Daiichi Sankyo takes another big whack at U.S. sales operations, cutting 280 jobs
Source: fierce